RCS - Solvonis Therapeutic - Solvonis Chair to speak at Lucid Capital Markets

Solvonis TherapeuticsAnnouncement

14/07/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250714:nRSN8962Qa&default-theme=true

RNS Number : 8962Q  Solvonis Therapeutics PLC  14 July 2025

14 July 2025
Solvonis Therapeutics plc

("Solvonis" or the "Company")

Solvonis Chair Dennis Purcell to speak at Lucid Capital Markets biotech
leadership event.

 

Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical
company developing novel medicines for addiction and mental health disorders
is pleased to announce that its Chairman, Dennis Purcell, will participate in
an exclusive investor event hosted by Lucid Capital Markets on Thursday, 17
July 2025 at 2:00pm ET.

The event, moderated by Elemér Piros, PhD, Managing Director and Senior
Biotech Analyst at Lucid Capital Markets, features a panel discussion with
three of the most influential figures in global biopharma: Dennis Purcell
(Chair, Solvonis; Founder, Aisling Capital), Stelios Papadopoulos (Chair,
Exelixis), and Jeremy Levin (Chair and CEO, Ovid Therapeutics).

The session will explore leadership, innovation, and strategic capital
deployment across the biotechnology sector.

Dennis Purcell brings more than 30 years of experience in life sciences
investment, having deployed over $15 billion in more than 200 companies
through Aisling Capital. His participation in this panel underscores the
strength of strategic leadership at Solvonis as the Company advances its
AI-enabled CNS drug discovery platform.

Event details:

Date: Thursday, 17 July 2025

Time: 2:00pm ET / 7:00pm BST

Registration link: https://lnkd.in/eq5pWiFn (https://lnkd.in/eq5pWiFn)

 

Enquiries:

Solvonis Therapeutics plc

Anthony Tennyson, CEO & Executive Director

anthony@solvonis.com

Allenby Capital Limited (Financial Adviser and Joint Broker)

Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)

Guy McDougall (Sales & Corporate Broking)

+44 (0) 20 3328 5656

Singer Capital Markets (Joint Broker)

Phil Davies

+44 (0) 20 7496 3000

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical
company developing novel medicines for addiction and mental health disorders.
Headquartered in London and listed on the main market of the London Stock
Exchange, Solvonis is advancing a differentiated pipeline of repurposed and
novel compounds targeting high-burden neuropsychiatric conditions with
significant unmet need.

The Company's lead programmes address Alcohol Use Disorder (AUD) and
Post-Traumatic Stress Disorder (PTSD)-conditions affecting over 80 million
people across the UK, US, and EU4. Its lead asset, SVN-001, is currently in
Phase 3 for severe AUD in Europe and the UK. SVN-002 is preparing for a Phase
2b trial in the US targeting moderate to severe AUD. Solvonis also has a
preclinical PTSD programme leveraging novel serotonin-dopamine modulators
designed to enhance pro-social behaviour and long-term outcomes.

In addition, Solvonis is advancing an AI-supported discovery platform built on
a proprietary CNS compound library, with initial focus on depression and
stimulant use disorders. This initiative expands the Company's R&D
pipeline into earlier-stage innovation while maintaining strategic focus on
comorbid and underserved neuropsychiatric conditions.

With a capital-efficient model, dual development strategy, and near-term
partnering opportunities, Solvonis is positioned to generate value through
innovation in neuropsychiatry.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGPUWCMUPAGBW